Geron Corporation (GERN)
GERN Stock Price Chart
Explore Geron Corporation interactive price chart. Choose custom timeframes to analyze GERN price movements and trends.
GERN Company Profile
Discover essential business fundamentals and corporate details for Geron Corporation (GERN) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
31 Jul 1996
Employees
229.00
Website
https://www.geron.comCEO
Harout Semerjian
Description
Geron Corporation is an advanced-stage biopharmaceutical company dedicated to the creation and market introduction of treatments for myeloid blood cancers. Its primary drug candidate, imetelstat, is a telomerase inhibitor currently undergoing Phase 3 clinical evaluation. This therapy aims to suppress the unchecked proliferation of cancerous stem and progenitor cells characteristic of myeloid hematologic malignancies. Imetelstat is being developed to address low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. Established in 1990, Geron's corporate headquarters are located in Foster City, California.
GERN Financial Timeline
Browse a chronological timeline of Geron Corporation corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 5 Aug 2026
EPS estimate is -$0.01, while revenue estimate is $55.29m.
Earnings released on 6 May 2026
EPS came in at -$0.01 surpassing the estimated -$0.03 by +66.67%, while revenue for the quarter reached $51.84m , beating expectations by +2.47%.
Earnings released on 25 Feb 2026
EPS came in at -$0.03 matching the estimated -$0.03, while revenue for the quarter reached $48.02m , missing expectations by -4.78%.
Earnings released on 5 Nov 2025
EPS came in at -$0.03 surpassing the estimated -$0.04 by +18.19%, while revenue for the quarter reached $47.23m , missing expectations by -11.46%.
Earnings released on 6 Aug 2025
EPS came in at -$0.02 surpassing the estimated -$0.03 by +33.33%, while revenue for the quarter reached $49.04m , beating expectations by +3.66%.
Earnings released on 7 May 2025
EPS came in at -$0.03 surpassing the estimated -$0.04 by +25.00%, while revenue for the quarter reached $39.60m , missing expectations by -23.56%.
Earnings released on 26 Feb 2025
EPS came in at -$0.04 matching the estimated -$0.04, while revenue for the quarter reached $47.54m , beating expectations by +4.97%.
Earnings released on 7 Nov 2024
EPS came in at -$0.04 surpassing the estimated -$0.09 by +55.56%, while revenue for the quarter reached $28.27m , missing expectations by -54.52%.
Earnings released on 8 Aug 2024
EPS came in at -$0.10 surpassing the estimated -$0.11 by +9.09%, while revenue for the quarter reached $882.00k , beating expectations by +226.67%.
Earnings released on 2 May 2024
EPS came in at -$0.09 surpassing the estimated -$0.10 by +10.00%, while revenue for the quarter reached $304.00k , beating expectations by +12.59%.
Earnings released on 28 Feb 2024
EPS came in at -$0.09 surpassing the estimated -$0.10 by +10.00%, while revenue for the quarter reached $23.00k , missing expectations by -67.14%.
Earnings released on 2 Nov 2023
EPS came in at -$0.08 surpassing the estimated -$0.10 by +20.00%, while revenue for the quarter reached $164.00k , beating expectations by +134.29%.
Earnings released on 3 Aug 2023
EPS came in at -$0.09 falling short of the estimated -$0.08 by -12.50%, while revenue for the quarter reached $29.00k , missing expectations by -58.57%.
Earnings released on 11 May 2023
EPS came in at -$0.07 surpassing the estimated -$0.09 by +22.22%, while revenue for the quarter reached $21.00k , missing expectations by -73.75%.
Earnings released on 16 Mar 2023
EPS came in at -$0.10 surpassing the estimated -$0.11 by +9.09%, while revenue for the quarter reached $103.00k , missing expectations by -14.17%.
Earnings released on 3 Nov 2022
EPS came in at -$0.10 falling short of the estimated -$0.09 by -11.11%, while revenue for the quarter reached $297.00k , beating expectations by +240.73%.
Earnings released on 11 Aug 2022
EPS came in at -$0.07 surpassing the estimated -$0.09 by +22.22%, while revenue for the quarter reached $73.00k , missing expectations by -36.30%.
Earnings released on 9 May 2022
EPS came in at -$0.09 surpassing the estimated -$0.11 by +18.18%, while revenue for the quarter reached $123.00k , beating expectations by +20.29%.
Earnings released on 10 Mar 2022
EPS came in at -$0.10 falling short of the estimated -$0.08 by -25.00%, while revenue for the quarter reached $1.04m , beating expectations by +1.25k%.
Earnings released on 9 Nov 2021
EPS came in at -$0.08 surpassing the estimated -$0.09 by +11.11%, while revenue for the quarter reached $109.00k , beating expectations by +81.67%.
Earnings released on 16 Aug 2021
EPS came in at -$0.09 matching the estimated -$0.09, while revenue for the quarter reached $107.00k , beating expectations by +78.33%.
GERN Stock Performance
Access detailed GERN performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
